Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Congress Last Resort On IPRs After Supreme Court Backs Patent Board

Executive Summary

Biopharmaceutical industry lobbying efforts are expected to jump into overdrive on Capitol Hill to get Congress to ban the use of the broadest reasonable interpretation by the US Patent & Trademark Office Patent Trial and Appeal Board after the Supreme Court backed the standard for conducting inter partes reviews – trial proceedings created five years ago to be a faster and more affordable alternative to challenging patents in the courts.


Related Content

Innovators Employ Labyrinthine Defenses To Fend Off Biosimilars
Innovators Employ Labyrinthine Defenses To Fend Off Biosimilars
Supreme Court Outcome Unlikely To Dent IPR Popularity
BIO: Deals, Investment At Risk If IPR Course Unchanged
Inter Partes Reviews Just Got More Expensive
Will Supreme Court Lift 'IPR Pressure' Off Biopharma?
US Capitol Capsule: Patent Challenge Landscape Shifting: Inter Partes Reviews Climb





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts